| P50 | author | Raffaella Barbero | Q43168047 |
| | Petra Cagnardi | Q55743581 |
| | Giovanni Re | Q67819050 |
| P2093 | author name string | B Cuniberti | |
| | P Badino | |
| | C Girardi | |
| | R Odore | |
| P2860 | cites work | Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase | Q24563699 |
| | Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis | Q24646764 |
| | Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and predicting selectivity of nonsteroidal anti-inflammatory drugs in cats | Q28175675 |
| | Human pharmacology of naproxen sodium | Q28222704 |
| | Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells | Q28376695 |
| | Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides | Q28619497 |
| | Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets | Q33342580 |
| | Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs | Q35204610 |
| | Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-inda none (L-745,337), on the cyclo-oxygenase activity of human blood prostagl | Q35872952 |
| | Eltenac, a new anti-inflammatory and analgesic drug for horses: clinical aspects | Q39509027 |
| | Critical role of COX-1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone | Q42442777 |
| | Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers | Q43054314 |
| | Effects of the nonsteroidal anti-inflammatory drug naproxen on human erythrocytes and on cell membrane molecular models | Q43190781 |
| | Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. | Q43604445 |
| | Expression and activity of COX-1 and 2 and 5-LOX in joint tissues from dogs with naturally occurring coxofemoral joint osteoarthritis | Q43725388 |
| | In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats | Q43795388 |
| | Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. | Q44251219 |
| | Characterization of eltenac and novel COX-2 selective thiopheneacetic acid analogues in vitro and in vivo | Q46449987 |
| | COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis | Q46531185 |
| | Oral administration of tepoxalin in the horse: a PK/PD study. | Q51387865 |
| | Clinical pharmacology and therapeutic uses of non-steroidal anti-inflammatory drugs in the horse | Q70087294 |
| | Leukotrienes in the pathogenesis of NSAID-induced gastric and intestinal mucosal damage | Q72687835 |
| | Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse | Q73656847 |
| | Nonsteroidal anti-inflammatory drugs | Q74297732 |
| | Inhibition of cyclooxygenase-1 and cyclooxygenase-2 analysis of in vitro test systems and their clinical relevance | Q82944702 |
| | Molecular characterization of feline COX-2 and expression in feline mammary carcinomas | Q83256672 |
| P433 | issue | 3 | |
| P921 | main subject | pharmacodynamics | Q725307 |
| | tepoxalin | Q7701370 |
| | whole blood | Q7997549 |
| P304 | page(s) | 327-333 | |
| P577 | publication date | 2011-05-11 | |
| P1433 | published in | The Veterinary Journal | Q15752615 |
| P1476 | title | In vitro and ex vivo pharmacodynamics of selected non-steroidal anti-inflammatory drugs in equine whole blood | |
| P478 | volume | 191 | |